seitlicher Menuepunkt
SUCHE
Suchbegriff

SUCHE
 
seitlicher Menuepunkt
LOGIN

2016-01-01

Publikationen im Rahmen internationaler Kongresse

Studien, die im Rahmen internationaler Kongresse präsentiert wurden (2010-2015)

2015:

  1. Kiesewetter B, Greil R, Willenbacher W, Neumeister P, Fridrik MA, Markus R. AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma). Blood. 2015;126(23):3973-.
  2. Kreissl S, Goergen H, von Tresckow B, Behringer K, Markova J, Lohri A, et al. Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group. Blood. 2015;126(23):3941-.
  3. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, et al. Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data. Blood. 2015;126(23):2515-.
  4. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, et al. Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy? Blood. 2015;126(23):3742-.
  5. Schreiber V, Kitzmueller M, Buchner P, Weissenboeck N, Lichtneckert M, Greil R, et al. 2098 Assessment of pharmacokinetic (PK) interaction between cetuximab (CTX) and capecitabine (CCB) or oxaliplatin (OX) in metastatic colorectal cancer (mCRC) patients (pts) (AGMT_CAPECET_PK). European Journal of Cancer. 2015;51:S361.
2014:
  1. Greil R, Obrtlikova P, Smolej L, Kozak T, Steurer M, Andel J, et al. Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial. Blood. 2014;124(21):20-.
  2. Kiesewetter B, Greil R, Willenbacher W, Neumeister P, Fridrik MA, Markus R. AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma). Blood. 2015;126(23):3973-.
  3. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstöcker M, et al. Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. Blood. 2014;124(21):955-.
  4. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstöcker M, et al. Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry. Blood. 2014;124(21):3681-.
  5. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstöcker M, et al. Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome. Blood. 2014;124(21):3683-.
  6. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstöcker M, et al. Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry. Blood. 2014;124(21):943-.
  7. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstöcker M, et al. Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry. Blood. 2014;124(21):2284-.
  8. Borchmann P, Haverkamp H, Lohri A, Kreissl S, Greil R, Markova J, et al. Addition of Rituximab to BEACOPPescalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study. Blood. 2014;124(21):500-.
  9. Rummel MJ, Viardot A, Greil R, Hertenstein B, Lerchenmüller C, Ganser A, et al. Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214). Blood. 2014;124(21):3052-.
  10. Ewald Woell, Peter Regitnig, Wolfgang Eisterer, Josef Thaler, Johnnes Gaenzer, Alois Wuestner, Alois Lang, Johannes Andel, Michael A. Fridrik, Richard Greil Prospective screening for human epidermal growth factor receptor 2 (HER2) positivity in patients with inoperable locally advanced or metastatic gastric or gastro-esophageal junction cancer. AGMT gastric-5. J Clin Oncol 32, 2014 (suppl; abstr e15037)
  11. Stefan Kubicka, Richard Greil, Thierry André, Jaafar Bennouna, Javier Sastre, Eric Van Cutsem, Roger Von Moos, Pia J. Osterlund, Priti Hegde, Martina A. Sersch, Stuart Osborne, Frank Hermann, Dirk Arnold, on behalf of the ML18147 Study Investigators Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study. J Clin Oncol 32, 2014 (suppl 3; abstr 520)
2013:
  1. Egle A, Steurer M, Gassner FJ, Geisberger R, Melchardt T, Pleyer L, et al. Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results. Blood. 2013;122(21):4164-.
  2. Trneny M, Melzer H, Praxmarer M, Fridrik MA, Nawarawong W, Ben Yehuda D, et al. Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study. Blood. 2013;122(21):851-.
  3. Greil R, Von Moos R, Bennouna J, Osterlund PJ, Andre T, Van Cutsem E, et al. Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study. ASCO Meeting Abstracts. 2013;31(15_suppl):3604.
  4. Moehler MH, Ringshausen I, Hofheinz R, Al-Batran S-E, Mueller L, Thuss-Patience PC, et al. POWER: An open-label, randomized phase III trial of cisplatin and 5-FU with or without panitumumab (P) for patients (pts) with nonresectable, advanced, or metastatic esophageal squamous cell cancer (ESCC). ASCO Meeting Abstracts. 2013;31(15_suppl):TPS4158.
  5. Woell E, Keil F, Thaler J, Gruenberger B, Hejna M, Eisterer W, et al. Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: Final efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the arbeitsgemeinschaft Medikamentose tumortherapie (AGMT). ASCO Meeting Abstracts. 2013;31(15_suppl):e15041.
  6. Kubicka S, Von Moos R, Greil R, Sastre J, Osterlund PJ, Arnold D, et al. Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147. ASCO Meeting Abstracts. 2013;31(4_suppl):452.
  7. Ulrich Jaeger, Marek Trneny, Helen Melzer, Michael Praxmarer, Michael A. Fridrik, We-erasak Nawarawong, Dina Ben Yehuda, Biljana Mihaljevic, Osman Ilhan, Veronika Ballova,, Michael Hedenus, Liang-Tsai Hsiao, Wing-Yan Au, Josef Thaler, Gerhard Weidinger, Felix Keil, Christian Dittrich, Cathrin Skrabs, Anton Klingler, Richard Greil, and the NHL13 investigators. A multicentre, randomized, phase III study of rituximab as maintenance treatment versus observation alone in patients with aggressive B-cell lymphoma: The AGMT NHL13 trial. EHA 2013
2012:
  1. Arnold D, Andre T, Bennouna J, Sastre J, Osterlund PJ, Greil R, et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). ASCO Meeting Abstracts. 2012;30(18_suppl):CRA3503.
  2. Woell E, Thaler J, Keil F, Eisterer W, Fridrik MA, Gruenberger B, et al. Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: First efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentose Tumortherapie. ASCO Meeting Abstracts. 2012;30(15_suppl):4074.
  3. E. Woell, F. Keil, J. Thaler, B. Gruenberger, M. Hejna, W. Eisterer, M. A. Fridrik, F. Romeder, R. Greil; Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: First efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie. ESMO 2012
  4. M. Troch, B. Kiesewetter, W. Willenbacher, E. Willenbacher, A. Zebisch, W. Linkesch, M. A. Fridrik, L. Müllauer, R. Greil, M. Raderer. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated tissue (MALT-lymphoma): a phase II study by the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). ESMO 2012
  5. F. Keil, E. Selzer, A. Berghold, K. Kapp, A. De Vries, R. Greil, S. Reinisch, W. Anderhuber, M. Burian, G. Kornek. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. ESMO 2012
2011:
  1. Woell E, Keil F, Thaler J, Gruenberger B, Hejna M, Eisterer W, et al. Oxaliplatin, irinotecan, and bevacizumab followed by docetaxel and bevacizumab in inoperable gastric cancer: First results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). ASCO Meeting Abstracts. 2011;29(15_suppl):e14502.
  2. Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(32):4234-42.
  3. Egle A, Steurer M, Gassner F, Geisberger R, Melchardt T, Weiss L, et al. A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results. Blood. 2011;118(21):292-.
  4. Fridrik MA, Petzer AL, Keil F, Willenbacher W, Jaeger U, Lang A, et al. Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial. Blood. 2011;118(21):2676-.
  5. Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, et al. Report on Response and Overall Survival of 128 Unselected, Consecutive AML Patients From the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. Blood. 2011;118(21):4266-.
  6. Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstöcker M, et al. Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. Blood. 2011;118(21):1715-.
  7. Auberger J, Pleyer L, Weiss L, Egle A, Greil R. Azacitidine Is Feasible and Safe in Patients with MDS and Co-Existing Plasma Cell Dysplasias (PCD) - Report on 9 Patients From the Austrian Azacitidine Registry (AAR). Blood. 2011;118(21):5056-.
  8. d'Amore F, da Silva MG, Leppa S, Relander T, Pezzutto A, Lauritzsen GF, et al. First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant. Blood. 2011;118(21):4110-.
  9. Pleyer, L.; Stauder, R.; Thaler, J.; Ludwig, H.; Pfeilstoecker, M.; Steinkirchner, S.; Melchardt, T.; Weltermann, A.; Lang, A.; Linkesch, W.; Krippl, P.; Fridrick, M.; Egle, A.; Greil, R. Overall survival data of patients with MDS, AML and CMML from the Austrian Azacitidine Registry of 184 consecutive patients Leukemia. Research 2011; 35, Suppl 1: 450-450.-The 11th International Symposium on Myelo-dysplastics Syndroms; May 18-20, 2011; Edinburgh, GB
  10. Pleyer, L.; Stauder, R.; Thaler, J.; Ludwig, H.; Pfeilstoecker, M.; Steinkirchner, S.; Melchardt, T.; Weltermann, A.; Lang, A.; Linkesch, W.; Krippl, P.; Fridrick, M.; Egle, A.; Greil, R. Age- and comorbidity-specific evaluation of Azacitidine treatment, response and overall survival in 184 patients in the Austrian Azacitidine Registry. Leukemia Research 2011; 35, Suppl 1: 457-457.-The 11th International Symposium on Myel-odysplastics Syndroms; May 18-20, 2011; Edinburgh, GB
2010:
  1. Fridrik M, Petzer AL, Keil F, Willenbacher W, Jäger U, Lang A, et al. Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14). Blood. 2010;116(21):1766-.
  2. Egle A, Weiss L, Melchardt T, Gunsilius E, Petzer AL, Fridrik M, et al. Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The…. Blood. 2010;116(21):1380-.
  3. Engert A, Borchmann P, Pluetschow A, von Tresckow B, Markova J, Hitz F, et al. Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2010;116(21):765-.
  4. Egle A, Melchardt T, Weiss L, Steurer M, Greil R. The BENDALEM CLL 6 AGMT Study – Bendamustine Combined with Alemtuzumab In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis. Blood. 2010;116(21):4633-.


zurück zur Übersicht